Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, a novel subcutaneously administered ADC delivering a potent glucocorticoid directly to immune cells, at the European Congress of Rheumatology (EULAR) 2026 in London, UK, June 3-6, 2026. The Phase 1 data from healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity with no impact on serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
The initial results indicate that LFD-200 may offer a new treatment approach for rheumatoid arthritis (RA) and other autoimmune conditions by delivering glucocorticoids directly to target cells, potentially avoiding the systemic side effects associated with traditional steroid therapies. Dosing in patients with moderate to severe RA in the ongoing Phase 1 study is expected to yield data by year-end 2026. The full announcement, including downloadable images and bios, is available here.
Lifordi’s lead ADC, LFD-200, leverages the success of ADCs in oncology to target immune cells in inflammatory diseases. The company has also applied its drug delivery approach to other payloads, including antisense oligonucleotides, siRNA, and small molecules. Backed by investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is committed to transforming the treatment of immune and inflammatory diseases.
